Sign Up Today and Learn More About Pathway Genomics Stock

Invest in or calculate the value of your shares in Pathway Genomics or other pre-IPO companies through EquityZen's platform.

Get Started

Pathway Genomics Stock

Genetic DNA Testing Company

About Pathway Genomics Stock

Founded

2008

Headquarters

San Diego, CA, US

Notable Investor

IBM Ventures

Total Funding

43.0M

Pathway Genomics provides a comprehensive set of genomic testing services across the healthcare spectrum, including tests for general health and wellness, liquid biopsy, pharmacogenomics, hereditary cancer risk and carrier screening. Its general health and wellness tests, including PathwayFit®, Cardiac DNA Insight®, and SkinFit™, equip physicians and patients with genetic information to support lifestyle choices. Liquid biopsy tests, including CancerIntercept™ Detect and Monitor, are non-invasive tests for detection of circulating tumor DNA. Pathway’s pharmacogenomics tests (Mental Health DNA Insight® and Pain Medication DNA Insight®) provide genetic information to help guide selection of optimal medication for management of mental health and pain disorders. Pathway’s hereditary cancer risk tests, including BRCATrue® and ColoTrue®, evaluate genetic factors for future cancer risk. Pathway Genomics Corporation operates a clinical laboratory to provide its commercial genetic testing services to physicians and their patients in the United States and internationally. Pathway Genomics Corporation was incorporated in 2008 and is based in San Diego, California.

Investors in Pathway Genomics

Discover investors in Pathway Genomics stock and explore their portfolio companies

Pathway Genomics Management

Leadership team at Pathway Genomics

Chief Laboratory Officer & Medical Director

Nilesh Dharajiya, M.D.

Chief Business Officer

K'Lene Oen

Locked Features

Join now and verify your accreditation status to gain access to:

  • Pathway Genomics current valuation
  • Pathway Genomics stock price
  • Available deals in Pathway Genomics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Pathway Genomics stock?

Accredited investors can buy pre-IPO stock in companies like Pathway Genomics through EquityZen funds. These investments are made available by existing Pathway Genomics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Pathway Genomics stock?

Shareholders can sell their Pathway Genomics stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."